Gastrin-Releasing Peptide Receptor Targeting in Cancer Treatment: Emerging Signaling Networks and Therapeutic Applications

Mikko O. Laukkanen, Maria Domenica Castellone

Research output: Contribution to journalArticlepeer-review

Abstract

Growth factors of the bombesin/gastrin releasing peptide (BN/GRP) family play a critical role in proliferation and progression of malignancies. Inhibitors targeting GRP signalling have been developed and tested as anticancer compounds showing promising preclinical and early phase clinical results. In this review, we will discuss the molecular signaling, expression and the functional role of BN/GRP-GRPR in different cancer models and will focus on the available strategies to target BN/GRP-GRPR in cancer treatment as well as in tumour diagnosis and follow up.

Original languageEnglish
Pages (from-to)508-514
Number of pages7
JournalCurrent Drug Targets
Volume17
Issue number5
Publication statusPublished - Apr 1 2016

Keywords

  • Cancer
  • Clinical trial
  • Drug targets
  • Neuropeptide
  • Signaling transduction

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Fingerprint

Dive into the research topics of 'Gastrin-Releasing Peptide Receptor Targeting in Cancer Treatment: Emerging Signaling Networks and Therapeutic Applications'. Together they form a unique fingerprint.

Cite this